Back to dashboard
CommercialCoverageMedium impact

Serologic Diagnosis of Celiac Disease

Blue Cross & Blue Shield of Mississippi·MS · Gastroenterology, Family Medicine, Internal Medicine +2 more·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply

Summary

BCBS Mississippi updated their medical policy for celiac disease serologic testing, establishing specific criteria for when antibody testing is medically necessary versus investigational. The policy limits certain antibody tests to once per lifetime and restricts antigliadin antibody testing to children under 24 months.

Action Required

Action needed
Immediately: Billing team must review all celiac disease antibody test orders to ensure medical necessity criteria are met per BCBS MS policy L.2.04.425. Verify patients have appropriate symptoms and common pathogens have been ruled out before submitting claims. Flag deamidated gliadin peptide antibody tests as investigational and likely to be denied. Educate providers on lifetime limits for tissue transglutaminase and antigliadin antibody testing.